10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Emerging US biotech Tyme Technologies saw its shares leap 13.6% to $1.75 in unusually heavy volume, on news of a potential $40 million deal with Eagle Pharmaceuticals focused on the co-promotion of Tyme's lead CMBT candidate oral SM-88 in advanced cancers. 8 January 2020
Adding to the list of marketing clearances for the drug, now Health Canada has approved Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (MTX). 7 January 2020
Shares of US biotech Protagonist Therapeutics gained more than 4% to $6.96 by mid-morning, after it revealed a milestone payment under its 2017 collaboration with Johnson & Johnson unit Janssen Biotech. 7 January 2020
Velabs Therapeutics and fellow German firm Alytas Therapeutics have agreed a licensing deal for the development and commercialization of certain of the latter’s antibodies. 7 January 2020
The former executive team of Swiss biotech Therachon has founded a new company, VectivBio, with $35 million in financing to target serious rare diseases. 7 January 2020
CNS specialist AlzeCure Pharma has exclusively in-licensed a vanilloid receptor subtype 1 (VR1) project targeting neuropathic pain from fellow Swedish company Acturum Life. 7 January 2020
US biotech firm FibroGen has appointed Enrique Conterno as the company’s chief executive and a member of the board of directors, effective immediately. 7 January 2020
Keytruda (pembrolizumab) is already approved in five lung cancer indications, but the Merck & Co drug does not have the market entirely cornered, new data shows. 7 January 2020
Dutch antibody-drug conjugate (ADC) specialist Synaffix and Shanghai Miracogen have expanded an existing collaboration with an agreement to develop and commercialize a second product candidate. 7 January 2020
A subsidiary of Japanese group Kyorin Holdings has acquired an exclusive license to develop and commercialize a candidate for interstitial lung diseases in Japan from California’s aTyr Pharma. 7 January 2020
US clinical-stage biopharma firm Pulmatrix today announced that it has entered into a research collaboration with fellow USA-based Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery. 6 January 2020
There was good news for Germany’s Merck KGaA and US partner Pfizer today as they announced the Phase III JAVELIN Bladder 100 study with their PD-L1 antibody Bavencio (avelumab) met its primary endpoint of overall survival (OS) at the planned interim analysis. 6 January 2020
The National Institute of Health and Care Excellence (NICE) has issued draft guidance not recommending Waylivra (volanesorsen) as a treatment for familial chylomicronaemia syndrome (FCS) on the National Health Service (NHS) in England. 3 January 2020
US drugmaker Incyte Corporation looked set to open Friday’s trading more than 11% down after taking an after-hours pummelling in the stock market. 3 January 2020
Californian biotech Durect Corporation lost almost a third of its value in the stock market on Thursday after the company announced disappointing results from its study of DUR-928 in mild to moderate plaque psoriasis. 3 January 2020
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024